Printer Friendly

T CELL SCIENCES AND SMITHKLINE BEECHAM ANNOUNCE IND FILING FOR SCR1 FOR THE TREATMENT OF ADULT RESPIRATORY DISTRESS SYNDROME

T CELL SCIENCES AND SMITHKLINE BEECHAM ANNOUNCE IND FILING FOR SCR1
 FOR THE TREATMENT OF ADULT RESPIRATORY DISTRESS SYNDROME
 CAMBRIDGE, Mass., Aug. 4 /PRNewswire/ -- T Cell Sciences, Inc. (NASDAQ: TCEL), announced today that its partner SmithKline Beecham, filed an Investigational New Drug (IND) application with the Food and Drug Administration to begin human clinical trials of sCR1 for the treatment of adult respiratory distress syndrome (ARDS). sCR1 is the first of a new class of compounds, called complement inhibitors, which may minimize inappropriate tissue damage which occurs in a number of medical conditions.
 "The IND submission of the company's first therapeutic product candidate is a significant milestone in our history," said Alan W. Tuck, president and chief executive officer of T Cell Sciences. "This action marks the transition of T Cell Sciences from a research only company to a research and development stage biopharmaceutical company."
 The initial clinical trials will be conducted in burn patients at risk of developing ARDS, a life-threatening complication of burns, sepsis and trauma. After burn injury, fluid and white blood cells may infiltrate the lungs, which can lead to pulmonary failure. In preclinical animal studies, sCR1 reduced white blood cell activation and attraction and blood vessel permeability, which may lead to limiting the events which lead to ARDS.
 Approximately 250,000 patients in the U.S. are afflicted with ARDS and a significant number of sepsis, trauma and burn patients die from the syndrome. Burn injury-induced ARDS accounts for approximately 15 percent of the ARDS patient population.
 Located in Cambridge, T Cell Sciences, Inc. is utilizing proprietary T Cell and soluble receptor technology to develop pharmaceutical products to treat diseases of inflammation, autoimmunity and cancer. T Cell Diagnostics, an 84 percent-owned subsidiary of T Cell Sciences, develops, manufactures and markets innovative diagnostic and research products.
 SmithKline Beecham -- one of the world's leading healthcare companies -- discovers, develops, manufactures and markets human and animal pharmaceuticals, over-the-counter medicines and clinical laboratory testing services.
 -0- 8/4/92
 /CONTACT: Allan W. Tuck, president and CEO, or Susan Primrose, corporate development and communications for T Cell Sciences, 617-621-1400; and Sharyn M. Arnold, SmithKline Beecham, 215-751-7074/
 (TCEL) CO: T Cell Sciences, Inc.; SmithKline Beecham ST: Massachusetts IN: MTC SU: JVN


TM -- NE007 -- 6596 08/04/92 11:04 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Aug 4, 1992
Words:378
Previous Article:SPRINT EXPANDS VIDEOCONFERENCING WITH PICTURETEL STRATEGIC ALLIANCE
Next Article:NEWCOR FINALIZES PURCHASE OF MIDWEST RUBBER COMPANY
Topics:


Related Articles
FDA APPROVES SMITHKLINE BEECHAM'S TRIOSTAT(TM) FOR TREATMENT OF MYXEDEMA COMA; RECEIVES ORPHAN DRUG STATUS FOR POTENTIALLY DEADLY SYNDROME
T CELL SCIENCES AND SMITHKLINE BEECHAM AGREE TO MODIFY SCR1 DEVELOPMENT AND LICENSE AGREEMENT
sCR1 CLINICAL DEVELOPMENT TRANSFERRED TO T CELL SCIENCES
TCELL SCIENCES PRESENTS INITIAL DATA ON NOVEL COMPLEMENT/CELL ADHESION INHIBITOR FOR THE TREATMENT OF INFLAMMATORY CONDITIONS
T CELL SCIENCES RECEIVES ORPHAN DRUG DESIGNATION FOR sCR1 IN ARDS
GERMANY IS FIRST WORLDWIDE LAUNCH FOR SMITHKLINE BEECHAM'S NEW ACELLULAR PERTUSSIS VACCINE, INFANRIX
T CELL SCIENCES COMPLETES PHASE 1 CLINICAL TRIAL WITH TP10 IN ARDS
SMITHKLINE BEECHAM AND THERATECH ANNOUNCE NATIONWIDE AVAILABILITY OF ANDRODERM
SMITHKLINE BEECHAM'S HYCAMTIN FOR RECURRENT OVARIAN CANCER RECOMMENDED FOR APPROVAL BY FDA COMMITTEE
Hycamtin Shows Promising Results as Combination Therapy In Patients With Leukemia

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters